Rocket One Inc. (RKTO) Stock Price & Analysis
Rocket One Inc. (RKTO) fell 5.81% to USD 0.79 as of July 25, 2026 at 04:19 UTC, according to Nexqual real-time market data.
RKTO last closed at USD 0.84; the session ranged USD 0.79–0.84 on volume of 559,208 shares. Market capitalization is $17.66M, with a 52-week range of USD 0.49–2.45 (NCM). Source: Nexqual, July 25, 2026 at 04:19 UTC.
Key Statistics (as of July 25, 2026 at 04:19 UTC)
| Price | USD 0.79 |
|---|---|
| Change | ▼ 5.81% (down) |
| Previous Close | USD 0.84 |
| Open | USD 0.84 |
| Day Range | USD 0.79 – 0.84 |
| 52-Week Range | USD 0.49 – 2.45 |
| Volume | 559,208 shares |
| Market Cap | $17.66M |
| Exchange | NCM |
Technical Analysis (RKTO)
Nexqual's technical model rates RKTO "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 04:19 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.09 (neutral) |
| vs SMA50 | Below (USD 1.04) |
| MACD | -0.06 (negative) |
Analyst Ratings (RKTO)
Wall Street analysts rate RKTO "None", per Nexqual as of July 25, 2026 at 04:19 UTC.
| Consensus Rating | None |
|---|
Earnings (RKTO)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.16 vs est -0.1 ▼ miss |
| 2025-09-30 | USD -0.3 vs est -0.07 ▼ miss |
| 2025-06-30 | USD -0.17 vs est -0.14 ▼ miss |
| 2025-03-31 | USD -0.27 vs est -0.34 ▲ beat |
Source: Nexqual, July 25, 2026 at 04:19 UTC.
Financials & Fundamentals (RKTO)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -148.85% |
| Current Ratio | 3.39 |
| Total Cash | $4.05M |
| Total Debt | $0 |
| Free Cash Flow | $-5.07M |
Source: Nexqual, July 25, 2026 at 04:19 UTC.
Financial Health Score (RKTO)
Nexqual rates Rocket One Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 04:19 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $4M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$10M |
| Efficiency | Critical — ROE -149%, ROA -80.3% |
Ownership (RKTO)
| Insider Ownership | +2.63% |
|---|---|
| Institutional Ownership | +3.83% |
| Shares Outstanding | 22.32M |
| Float | 18.57M |
| Short % of Float | +13.75% |
Source: Nexqual, July 25, 2026 at 04:19 UTC.
Leadership (RKTO)
Rocket One Inc. is led by Robb Knie (age 56), Founder, President, CEO & Chairman, per Nexqual as of July 25, 2026 at 04:19 UTC.
| Founder, President, CEO & Chairman | Robb Knie (age 56) |
|---|---|
| Chief Financial Officer | David S. Briones (age 49) |
| Executive Vice President of Operations | Hayley Springer |
Major Backers & Investors (RKTO)
Notable institutional backers of Rocket One Inc. include Fidelity, UBS Group AG, Lido Advisors, LLC, according to Nexqual as of July 25, 2026 at 04:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.82% |
| UBS Group AG | 0.71% |
| Lido Advisors, LLC | 0.17% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.54% |
| Geode Capital | 0.96% |
| State Street | 0.29% |
| Northern Trust | 0.19% |
Source: Nexqual, July 25, 2026 at 04:19 UTC.
From Rocket One Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)
Key Strengths & Strategy (as disclosed to the SEC)
- The BioLexa Platform is a proprietary, patented, drug compound platform for the treatment of eczema.
- In the U.S., the FDA regulates such products under the FDCA and the Public Health Services Act and implements related regulations.
- Our policy is to actively seek the broadest intellectual property protection possible for our products, proprietary information and proprietary technology through a combination of contractual arrangements and patents, both in the U.S. and elsewhere in the world.
- The license enables us to develop the platform for any indications in humans.
Partnerships
- Proceeding under this regulatory pathway, we will be able to rely upon publicly available data with respect to our active ingredient in our NDA submission to the FDA for marketing approval.   On June 7, 2021, we entered into a sponsored research agreement with Washington University in St.
- At this time, we do not anticipate conducting any further trials in Australia.   Preclinical Development   HT-004   On November 20, 2019, we entered into a license agreement with NC State pursuant to which NC State granted us an exclusive license to HT-004 for treating allergic diseases.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PHIO | Phio Pharmaceuticals Corp. | USD 1.04 | ▼ 1.89% |
| ADTX | Aditxt, Inc. | USD 0 | ▲ 33.33% |
| PSTV | PLUS THERAPEUTICS, Inc. | USD 3.83 | ▲ 0.26% |
| PALI | Palisade Bio, Inc. | USD 1.95 | ▲ 2.63% |
| ENVB | Enveric Biosciences, Inc. | USD 1.29 | ▼ 3.73% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:19 UTC. This page is informational and not investment advice.